LARIMAR THERAPEUTICS, INC. Total Liabilities and Equity
LARIMAR THERAPEUTICS, INC. (LRMR) had Total Liabilities and Equity of $165.30 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-04
- 2026-06-30: Liabilities and Equity $165.30M.
- 2026-03-31: Liabilities and Equity $208.51M.
- 2025-12-31: Liabilities and Equity $145.84M.
- 2025-09-30: Liabilities and Equity $187.35M.
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2026-06-30 | $165.30M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $208.51M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $145.84M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $187.35M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $149.99M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $170.18M 10-Q · filed 2025-04-30 | |
| 2024-12-31 | $200.22M 10-K · filed 2026-03-19 | |
| 2024-09-30 | $219.02M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $237.16M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $248.21M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $95.94M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $103.95M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $111.72M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $118.91M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $126.41M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $133.01M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $62.85M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $71.22M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $78.67M 10-K · filed 2023-03-14 | |
| 2021-09-30 | $87.94M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $80.93M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $93.02M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $104.69M 10-K · filed 2022-03-25 | |
| 2020-09-30 | $113.96M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $125.46M 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $73.70M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $5.20M 10-K · filed 2021-03-04 | $80.73M 10-K · filed 2020-03-05 |
| 2019-09-30 | $92.89M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $103.88M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $110.19M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $121.76M 10-K · filed 2020-03-05 | |
| 2018-09-30 | $131.94M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $79.80M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $92.61M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $105.51M 10-K · filed 2019-03-14 | |
| 2017-09-30 | $96.26M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $108.84M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $119.37M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $131.62M 10-K · filed 2018-03-09 | |
| 2016-09-30 | $142.71M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $154.83M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $170.03M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $189.11M 10-K · filed 2017-03-10 | |
| 2015-09-30 | $207.45M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $222.60M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | $236.72M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | $117.52M 10-K · filed 2016-03-15 | |
| 2014-09-30 | $129.64M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $136.97M 10-Q · filed 2014-08-14 | |
| 2013-12-31 | $38.14M 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |